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112Vancomycin Removal During High-Volume
Peritoneal Dialysis in Acute Kidney Injury
Patients: A Prospective Cohort Clinical
Study
Daniela Ponce1,2, Welder Zamoner1, Fernanda Moreira Freitas1, André Balbi1 and
Linda Awdishu3
1São Paulo State University-UNESP, Rubião Junior District, without number Botucatu, São Paulo, Brazil; 2University of Sao
Paulo-USP, Bauru School of Medicine, Bauru, Sao Paulo, Brazil; and 3UC San Diego Skaggs School of Pharmacy and Phar-
maceutical Sciences, University of San Diego, California, USAIntroduction: Vancomycin pharmacokinetic data in patients with acute kidney injury (AKI) on high-volume
peritoneal dialysis (HVPD) are lacking. The aims were to study the pharmacokinetics of i.v. vancomycin in
patients with AKI treated by HVPD who received an i.v. dose of vancomycin (15–20 mg/kg), to determine
the vancomycin removal, and to establish vancomycin dosing and evaluation pharmacokinetics target
attainment achievement for the empirical treatment of patients with AKI treated by HVPD.
Methods: Vancomycin was administered 1 hour before dialysis start. Samples of all dialysate were
collected for a 24-hour period. Blood samples were collected after 1, 2, 4, and 24 hours of therapy. Van-
comycin concentrations were determined using a liquid chromatographic (high-performance liquid
chromatography)–fluorescence method. Pharmacokinetic calculations were completed assuming a
1-compartment model.
Results: Ten patients completed the study. The mean vancomycin dose administered was 18.0  2.95 mg/
kg (14.7–21.8 mg/kg) on the day of study (first day) and the mean percentage of vancomycin removal by
HVPD was 21.7%  2.2% (16%–29%). Peritoneal clearance was 8.1  2.2 ml/min (5.3–12 ml/min). The serum
vancomycin half-life was 71.2  24.7 hours (42–110 hours) during HVPD session, the maximum serum
concentration was 26.2  3.5 mg/l, which occurred 1 hour after vancomycin administration and HVPD start.
Area under the curve (AUC)0–24/minimum inhibitory concentration (MIC) ratio $400 was achieved in all
patients when MIC ¼ 1 mg/l was considered.
Conclusion: HVPD removes considerable amounts of vancomycin in septic patients with AKI. Adminis-
tration of 18 mg/kg vancomycin each 48 to 72 hours in patients with AKI undergoing HVPD was required to
reach and maintain therapeutic concentrations.
Kidney Int Rep (2019) 4, 112–118; https://doi.org/10.1016/j.ekir.2018.09.014
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).S epsis is the main etiology of AKI in critically illpatients and can reach the surprising mortality
rate of 70%.1–4 Current renal replacement therapy mo-
dalities include peritoneal dialysis (PD), intermittent he-
modialysis (conventional hemodialysis or prolonged
hemodialysis), and continuous renal replacement therapy.
Continuous methods are preferred in hemodynamically
unstable patients; however, previously published studies
have shown no difference in patient survival amongspondence: Daniela Ponce, São Paulo State University-
P, Rubião Junior District, Botucatu, São Paulo, Brazil.
l: dponce@fmb.unesp.br
ved 1 July 2018; revised 1 August 2018; accepted 19
mber 2018; published online 27 September 2018continuous renal replacement therapy, intermittent he-
modialysis, or PD.5
Recently, the interest in PD to manage patients with
AKI has been increased, mainly in developing coun-
tries, due to its lower cost and minimal infrastructural
requirements. Brazilian studies have shown that, with
careful thought and planning, patients with AKI can be
successfully treated using PD.6,7
Our previous studies have demonstrated that HVPD
can offer adequate small solute clearances and ultrafil-
tration using a flexible catheter, 2-l exchanges (total
dialysate volume ranged from 32 to 44 l per day) and 35-
to 60-minute dwell times. HVPD was rapidly effective in
the correction of blood urea nitrogen, creatinine, bicar-
bonate, and fluid overload. The achieved weekly Kt/VKidney International Reports (2019) 4, 112–118
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of distribution of urea) was 3.8  0.6 and the mortality
was 57%.6–8
Considering the high mortality rate of septic AKI
and its related costs of hospitalization and treatment,
the early administration of antimicrobials should be
adopted.
Vancomycin is an antibiotic used in the parenteral
treatment of infections caused by multidrug-resistant
gram-positive bacteria, especially methicillin-resistant
Staphylococcus aureus. Its antibacterial action is time-
dependent and concentration-independent.9,10 Based
on the pharmacodynamics of vancomycin, an AUC
(ratio) is recommended by the MIC (AUC/MIC) of 400 or
greater. Due to the logistic challenges of such deter-
mination in clinical practice, it was demonstrated that
such value could be obtained with trough serum levels
of vancomycin between 10 and 20 mg/l.9,11 A serum
level of less than 10 mg/l does not guarantee an AUC/
MIC ratio greater than 400 and may develop bacterial
resistance. However, the dosage above 20 mg/l can be
nephrotoxic.9,10
Vancomycin has almost exclusive renal elimination,
making dosage adjustment during kidney failure
obligatory. The half-life of vancomycin is 5 to 8 hours
in patients with normal kidney function and higher
than 180 hours in patients with advanced chronic
kidney disease.12–16 Volume of distribution of vanco-
mycin is 0.4 to 1.0 l/kg, molecular weight is approxi-
mately 1450 Da, and protein binding from 10% to
50%.16
Vancomycin is not removed to a significant extent
during PD and should be administered each 72 to 120
hours. However, there is no study that evaluated the
vancomycin removal during HVPD sessions in patients
with AKI and no strategies have been proposed to
appropriately dose vancomycin in HVPD.14–16
Our aim was to study the pharmacokinetics of i.v.
vancomycin in patients with AKI treated by HVPD
who received a single i.v. dose of vancomycin (15 mg/
kg), to determine the vancomycin removal, to compare
vancomycin levels obtained in blood with MICs of
typical gram-positive bacterial pathogens, to evaluate
pharmacokinetic target attainment achievement, and to
establish vancomycin dosing guidelines for the
empirical treatment of patients with AKI receiving
HVPD.METHODOLOGY
This was a prospective cohort clinical study performed
at the University Hospital Sao Paulo State in Botucatu
Medical School, Brazil. All procedures performed in
studies involving human participants were inKidney International Reports (2019) 4, 112–118accordance with the ethical standards of the institu-
tional and/or national research committee and with the
1964 Helsinki declaration and its later amendments or
comparable ethical standards.The study protocol was
approved by local ethics committees. Written informed
consent was obtained from patients or families. It was
not registered because it is not a clinical trial study. It
is a prospective cohort clinical study.
Ten critically ill adult patients with sepsis and AKI
treated by HVPD on vancomycin therapy were
included. Classification of AKI was made according to
Kidney Disease: Improving Global Outcomes criteria.17
All patients were oliguric (urine output lower than 0.5
ml/kg per hour). They were followed for 2 days after
introduction to the study.
PD was performed using a flexible catheter, an
automated cycler (HomeChoice; Baxter, Deerfield, IL),
and a high volume of dialysis fluid, as described in our
previous studies.6–8 Each session of HVPD lasted 24
hours, and sessions were repeated daily, 7 times per
week. The total dialysate volume per session ranged
from 32 to 38 l and the prescribed Kt/V was 0.50 per
session.
Vancomycin was administered 1 hour before dialysis
start. The protocol required that vancomycin 15 to 20
mg/kg was reconstituted with 100 ml 0.9% sodium
chloride and was administered for 1 hour. Blood sam-
ples were collected after 1, 2, and 4 hours of dialysis
start and end of dialysis (after 24 hours). Dialysate
samples were collected at the end of each dwell using a
sample port directly on the automatic cycler machine
for a 24-hour period. Vancomycin concentrations were
determined using a liquid chromatographic (high-per-
formance liquid chromatography)–fluorescence
method. Blood samples were placed in an ice bath and
centrifuged within 3 hours of collection. Serum was
transferred to a labeled polypropylene tube and stored
frozen at –80C until assayed. Volumes of dialysate and
of ultrafiltration were recorded for each patient.
Throughout, the analysis was carried out using a high-
performance liquid chromatography system (Agilent Se-
ries 1100; Agilent Technologies, Palo Alto, CA), according
to the protocol described by Hu et al.18 The following
pharmacokinetic parameters were calculated for each
patient assuming a 1-compartment model: volume of
distribution (Vd), dialysis total drug clearance (Cl), and
elimination half-life. The AUC was determined using the
trapezoidal rule to the last nonzero time point. The AUC
from the last nonzero time point was determined by the
pharmacokinetic method, concentration/k, where k is the
elimination rate constant determined from log-linear
regression of the terminal phase of the concentration-
time profile. A monoexponential model was used for all
pharmacokinetic calculations. The following equations113
CLINICAL RESEARCH D Ponce et al.: Vancomycin Removal During PD in Patientswere used: the serum elimination rate constant (k el) for
dwells was obtained by regression of the serum concen-
trations over the time between the start of the dwell and
the end of the dwell. The formula used to determine the
approximate serum concentration was C ¼ C 0 * e–k t,
where C ¼ concentration, C 0 ¼ original concentration,
–k ¼ elimination rate constant, and t ¼ time between
sampling points. The serum elimination half-life for pa-
tients on the cycler was calculated as (0.693)/(mean k el
dwells). The serum elimination half-life for patients off
the cycler was calculated as (0.693)/(mean k el dwells).
The serum AUC for the first 24 hours was calculated by
summation of the AUC of each dwell, using the trapezoid
rule, and from 24 hours to infinity by extrapolation of the
serum concentration at 24 hours/k el last dwell.
Data are expressed as median and range. The van-
comycin removal from blood during the HVPD session
was calculated from the following formula and
expressed as % vancomycin removed:
%Vancomycin removal ¼
ð½CpreHVPD C24hHVPD=CpreHVPDÞ  100;
where CpreHVPD ¼ the concentration of vancomycin before
HVPD, and C24hHVPD ¼ the concentration of vancomycin
at end of HVPD.
Sample Size Calculation
This study was performed to estimate the mean amount
of vancomycin removed by HVPD and to establish an
80% confidence interval about that value such that the
width was less than 20%, using a ¼ 0.05, b ¼ 0.2,
and standard sample size equations for parametric data;
it was estimated that 10 patients were required.19
RESULTS
Table 1 shows the patients and clinical characteristics.
All patients had sepsis or septic shock. The main bacterial
agents were gram-positive Staphylococcus haemolyticus,
methicilin-resistant S aureus, and Enterococcus faecalis.
All patients were in stage 3 according to Kidney Disease:Table 1. Patients’ demographic and clinical characteristics
Patient Sex Age, yr Weight, kg SOFA Di
1 F 58 65 11 Pn
2 F 62 55 12 End
3 F 59 58 14 M
4 M 76 71 13 Pn
5 M 72 62 12 Pe
6 M 59 58 14 M
7 F 44 75 13 Pn
8 M 67 68 12 Bloo
9 M 63 72 13 Bloo
10 M 72 62 14 Pe
F, female; M, male; MRSA, methicillin-resistant Staphylococcus aureus; SOFA, Sequential Org
114Improving Global Outcomes criteria of AKI.17 Mean
glomerular filtration rate according to MDRD was 0.3 ml/
min (0 to 0.74 ml/min). The mean dwell times for cycles
ranged from 35 to 50 minutes and 7 patients were anuric.
Vancomycin removal by HVPD was 21.7%  2.2%
(16%–29%). Vancomycin serum concentrations higher
than 15 mg/l at the day of study dialysis were obtained
in all patients at the end of dialysis. The median van-
comycin dose was 18  2.95 mg/kg (14.7–21.8 mg/kg)
on the day of study (first day). In all patients, it was the
first vancomycin dose administered.
AUC0–24/MIC ratio $ 400 was achieved in all pa-
tients on the study days (Table 2), when MIC ¼ 1 mg/l
was considered. Table 2 shows the vancomycin phar-
macokinetic parameters.
The mean serum and dialysate concentrations
remained in excess of MICs for sensitive organisms
(approximately 1 mg/l) in all patients during the treat-
ment. The mean vancomycin peak serum concentration
was 26.2  3.5 mg/l, which occurred 1 hour after van-
comycin administration and HVPD start. The mean dwell
dialysate concentration was 7.3  1.77 mg/l. Figure 1
shows serum vancomycin concentrations during HVPD
therapy.
Peritoneal clearance was 8.1  2.2 ml/min (5.3–12
ml/min) and vancomycin half-life during dialysis was
71.2  24.7 hours (42–110 hours).DISCUSSION
The purpose of this study was to characterize the
pharmacokinetics of vancomycin and provide dosing
recommendations based on a single i.v. 15-mg/kg dose
of vancomycin in patients with AKI treated by HVPD
(prescribed Kt/V of 0.5 per session) using 18 to 24
cycler exchanges over 24 hours.
Although the pharmacokinetics of vancomycin have
been studied in chronic patients on continuous
ambulatory PD, the data are limited for automated PD
and there were no data in HVPD. Vancomycin clear-
ance is minimal during continuous ambulatory PD andagnosis Pathogen/MIC Urine output, ml/kg per h
eumonia MRSA 0
ocarditis Enterococcus 0.32
eningitis MRSA 0.38
eumonia Staphylococcus haemolyticus 0.40
ritonitis Enterococcus 0
eningitis MRSA 0
eumonia MRSA 0
d Stream Enterococcus 0.44
d Stream MRSA 0
ritonitis Enterococcus 0.42
an Failure Assessment.
Kidney International Reports (2019) 4, 112–118
Table 2. PK/PD vancomycin parameters of individual patients
Patient
Doses,
mg/kg
C Van T1h,
mg/l
C Van T2h,
mg/l
C Van T4h,
mg/l
C Van T24h,
mg/l
C Van dialysate,
mg/l Half-life, h AUC/MIC Removal, %
Peritoneal Cl,
ml/min
Distribution
volume, l/kgVan Ur
1 15.3 22.5 19.4 17.3 16.8 9.5 42.2 424.4 25 12 12.5 0.68
2 21.8 28.6 27.7 25.1 23.8 5.6 64 568 16 8.8 10.8 0.85
3 17.2 24.5 21.3 19.3 17.9 8.2 52,4 424.5 25 9.2 11.5 0.7
4 21.3 28.2 27.6 25 23.1 6.1 105 557.4 18 5.7 8.2 0.74
5 16.1 22.2 19.7 19 17.8 8.1 52.6 422.5 23 8.3 9.7 0.72
6 17 24.5 21.2 17.3 16.9 9.3 65 490 24 6.8 9.1 0.73
7 13.5 32.7 28.6 27.1 25.9 8.1 77.5 605 2 9.7 13.4 0.61
8 19 26.6 22.4 19.6 18.8 9 53.4 448 29 5.3 9.8 0.65
9 14 24.6 22.3 21 20.5 5.2 110 477.5 16 8.1 11.4 0.7
10 22.3 22.1 19.6 19.2 17.7 8.2 77.6 401 22 8.6 10.5 0.62
AUC/MIC, area under the curve/minimum inhibitory concentration; C Van, serum concentration of vancomycin; Cl, clearance; Ur, urea.
D Ponce et al.: Vancomycin Removal During PD in Patients CLINICAL RESEARCHshould be administered approximately every 5 to 7
days,14 whereas during an automatic PD treatment, the
vancomycin clearance is significant, and should be
administered every 3 to 5 days. In a small study of 4
pediatric patients with peritonitis while on automated
PD, vancomycin serum concentrations decreased 17%
after the automated dialysis session.20,21 It was recom-
mended that vancomycin should be readministered to
maintain therapeutic serum concentrations. Dialysate
concentrations were not provided.
In this study, vancomycin removal mean was 21%
during HVPD. Previous study reported that it was 10%
in continuous ambulatory PD, 17% in automated PD,
and ranged from 17% to 31% in intermittent hemo-
dialysis therapy, according to flux membrane dialysis
used.14,22 Variability in vancomycin removal in HVPD
was modest (16% to 29%), and it is different from that
found in studies that described hemodialysis removal
using low- and high-flux dialysis. Peritoneal clearance
was 8.1  2.2 ml/min (5.3–12 ml/min), whereasFigure 1. Serum vancomycin concentrations during high-volume
peritoneal dialysis therapy.
Kidney International Reports (2019) 4, 112–118high-flux membranes have estimated vancomycin
clearance between 43.3 and 120.0 mL/min. Clearance of
vancomycin during PD may be affected by inflamma-
tion that affects peritoneal permeability and dialysate
flow. These conditions may lead to variability in van-
comycin clearance during PD dosage regimens in a
critical care setting.
Due to high pharmacokinetic variability in septic
patients with AKI, we suggest daily monitoring of
vancomycin concentrations to reach optimal trough
vancomycin concentrations and its dose may be read-
ministered every 48 to 72 hours to maintain therapeutic
serum concentrations in patients with AKI undergoing
HVPD. In hybrid and conventional hemodialysis
therapies, vancomycin dose should be administered
over the last hour of dialysis and vancomycin intra-
dialytic clearance was approximately 2-fold higher
with high-flux membrane compared with low-flux
membrane.22
The vancomycin peak serum concentration occurred
1 hour after vancomycin administration and HVPD
start, and vancomycin serum concentrations higher
than 15 mg/l were obtained in all patients at the end of
1 session of HVPD. Vancomycin half-life during HVPD
session was 71.2  24.7 hours (42–110 hours). Serum
and dialysate concentrations suggest that i.v. vanco-
mycin 18 mg/kg each 72 hours would provide adequate
concentrations over a 24-hour period.
An AUC/MIC ratio $400 is necessary to achieve
clinical effectiveness with vancomycin therapy.7 How-
ever, because it can be difficult in the clinical setting to
obtain multiple serum vancomycin concentrations to
determine AUC and subsequently calculate AUC/MIC,
trough serum concentration monitoring, which can be
used as a surrogate marker for AUC, is recommended as
the most accurate and practical method for vancomycin
monitoring. Trough vancomycin serum concentrations
maintained above 10 mg/l are recommended.9,11–13 All
our patients having vancomycin after 1 hour of dialysis115
CLINICAL RESEARCH D Ponce et al.: Vancomycin Removal During PD in Patientsstart serum concentrations above 10 mg/l, and AUC/MIC
of at least 400 was achieved in all patients on the study
days. This desired AUC/MIC ratio was achieved almost
only in patients with vancomycin MIC < 1.0 mg/l. In
patients with MIC $ 1.0 mg/l, higher dosing will be
required. A target AUC/MIC of $ 400 is not achievable
with conventional dosing methods if the pathogen van-
comycin MIC is $ 2 mg/l. Achievement of this ratio
would lead to undesirable vancomycin toxicity.9,11–13,16
Vancomycin-induced nephrotoxicity has been related
to drug plasma concentrations.9 Its incidence varies
greatly among various studies, with rates as low as zero
in the absence of other concomitant nephrotoxins, up to
40%23–26 in combination with other potentially nephro-
toxic drugs. Among the patient-related factors,27–30 the
most important are advanced age, reduced kidney func-
tion, dehydration, reduced renal mass, sex (women have
lower muscle mass and body water quantity), obesity,
hypoalbuminemia, and sepsis, whereas drug-related risk
factors include administration concomitant with other
nephrotoxic drugs, such as aminoglycosides, loop di-
uretics, amphotericin B, piperacillin-tazobactam,
acyclovir, vasopressors, and i.v. contrast media; as well
as long treatment duration and high serum dosage of this
antimicrobial.24–29 Data suggesting a causal relationship
between doses and therapeutic targets of vancomycin and
nephrotoxicity are conflicting and marked by con-
founding factors.30 Although there is minimal evidence
supporting efficacy in maintaining therapeutic levels
between 15 and 20 mg/l, several studies have evaluated
the safety of this recommendation, comparing nephro-
toxicity rates above and below 15 mg/l levels.31 A sys-
tematic review and a meta-analysis conducted by van Hal
et al.31 included 15 studies in which trough serum levels
of vancomycin $15 mg/l were associated with a higher
risk of nephrotoxicity when compared with levels <15
mg/l (odds ratio 2.67, P < 0.01).
The pharmacokinetic parameters should not change.
However, in critically ill patients, drug pharmacoki-
netic parameters may be expected to change, especially
regarding absorption, distribution, and metabolism,
resulting in variations in serum levels. Thus, there is an
increased risk of overdosing and drug toxicity, or a
subtherapeutic dose and an increased risk of bacterial
resistance, infection by opportunistic germs, and
mortality.16,19,21
The removal of antimicrobials by different dialysis
therapies in critically ill patients is a complex issue. This
depends on the modality and intensity of dialysis, as well
as drug characteristics, such as water solubility, molec-
ular weight, and the extent of protein binding. There are
no validated guidelines to assist in antibiotic dose
adjustment in septic patients on acute renal supportive
therapy, and the extrapolated recommendations were116obtained from studies on noncritical patients with end-
stage chronic kidney disease receiving substitutive
renal therapy. Thus, because of the importance of main-
taining therapeutic levels of antimicrobial drugs, more
studies on this very complex subject are needed to reduce
microbial resistance and mortality.22,32,33
Our study has some limitations, as the small number of
patients studied and the dialysis elimination have been
considered the only route of vancomycin elimination. We
did not consider the role of renal and biliary elimination
of vancomycin as possible confounders in the vancomy-
cin plasma reduction. We also evaluated the pharmaco-
kinetics of i.v. vancomycin in patients with AKI treated
by HVPD (prescribed Kt/V of 0.5 per session). However,
recent studies have presented similar outcomes of pa-
tients with AKI treated with lower PD doses.34,35 Para-
piboon et al.35 presented a study using PD to treat 80
critically ill patients with AKI. This was a randomized
controlled trial comparing the 2 regimens recommended
in the International Society for Peritoneal Dialysis
guidelines, aimed at achieving target weekly Kt/V of 3.5
and 2.1, respectively.33 Patients were randomized 1:1 to
receive 1.5 l of PD fluid using manual PD and a single-bag
open system delivered either hourly (36 l/24 hours) or
every 2 hours (18 l/24 hours) for the first 48 hours.
Following this, they could perform exchanges less often,
based on metabolic parameters and fluid balance.
Seventy-five patients were included in the analysis. The
achieved weekly Kt/V was 2.26 in the low-intensity
group and 3.3 in the high-intensity group. There was
no significant difference in metabolic control, although
ultrafiltration was higher in the high-intensity group.
The mortality was 72% in the high-intensity and 63% in
the low-intensity groups (P ¼ 0.18), suggesting no
advantage to the higher-intensity treatment. Certainly,
when lower PD doses are used, the clearance of vanco-
mycicn and its pharmacokinetics can be different from
our results.
CONCLUSION
HVPD removes considerable amounts of vancomycin in
septic patients with AKI, and antibiotic underdosing is
undesirable in these patients. Application of 18 mg/kg
vancomycin each 48 to 72 hours in patients with AKI
undergoing HVPD was required to maintain thera-
peutic concentrations. Daily vancomycin serum con-
centration monitoring is recommended to maintain
therapeutic concentrations, and vancomycin pharma-
cokinetics in patients with AKI undergoing HVPD
warrants further investigation.
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